Operational Costs Compared: SG&A Analysis of Neurocrine Biosciences, Inc. and TG Therapeutics, Inc.

Biotech Giants' SG&A: A Decade of Divergence

__timestampNeurocrine Biosciences, Inc.TG Therapeutics, Inc.
Wednesday, January 1, 20141798600024518692
Thursday, January 1, 20153248000019886580
Friday, January 1, 20166808100012631689
Sunday, January 1, 201716990600021977998
Monday, January 1, 201824893200020759000
Tuesday, January 1, 201935410000020838000
Wednesday, January 1, 2020433300000121812000
Friday, January 1, 2021583300000152137000
Saturday, January 1, 202275270000083231000
Sunday, January 1, 2023887600000122706000
Monday, January 1, 20241007200000
Loading chart...

Igniting the spark of knowledge

A Decade of SG&A: Neurocrine Biosciences vs. TG Therapeutics

In the ever-evolving landscape of biotechnology, operational efficiency is paramount. Over the past decade, Neurocrine Biosciences, Inc. and TG Therapeutics, Inc. have demonstrated contrasting trajectories in their Selling, General, and Administrative (SG&A) expenses. Neurocrine Biosciences has seen a staggering increase of nearly 4,800% in SG&A expenses from 2014 to 2023, reflecting its aggressive expansion and operational scaling. In contrast, TG Therapeutics, while also experiencing growth, has maintained a more conservative increase of approximately 400% over the same period.

This divergence highlights the strategic differences between the two companies. Neurocrine's substantial investment in operational costs suggests a focus on rapid growth and market penetration, whereas TG Therapeutics appears to be adopting a more measured approach. As the biotech sector continues to grow, these strategies will undoubtedly shape the future trajectories of these companies.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025